Using BRET to measure insulin resistance and receptor cross-talk

使用 BRET 测量胰岛素抵抗和受体串扰

基本信息

项目摘要

DESCRIPTION (provided by applicant): Insulin resistance is present in all persons with type II diabetes, and understanding the causes of insulin resistance will lead to new treatments for this disease. To better understand the mechanisms involved in the development of insulin resistance, new techniques for studying insulin resistance in cell culture models are needed. The studies outlined herein will accomplish this objective through the use of a novel imaging technique, bioluminescence resonance energy transfer (BRET). BRET uses fluorescent intracellular reporters to measure enzyme activity and protein-protein interactions in real time in living cells, and has the potential to greatly advance our understanding of insulin signaling. One important yet undervalued aspect of cellular metabolic signaling is the role of receptor cross-talk. For example, in adipocytes, a balance exists between insulin signaling, favoring energy storage (lipogenesis), and catecholamine signaling, favoring energy release (lipolysis). Cross-talk between the receptors for these hormones plays a critical role in maintaining normal metabolic homeostasis. Because of cross-talk, abnormalities in insulin signaling affect not only insulin signaling pathways, but also catecholamine signaling pathways. We have shown that one important site of cross-talk between these two hormonal signaling systems is at the level of the receptor regulatory protein beta-arrestin. Using BRET, we will measure several aspects of the interaction between the insulin receptor (and the IGF-1 receptor) and beta-arrestin. BRET also gives us an unprecedented ability to measure the kinetics of insulin signaling in real time in live cells. Abnormal kinetics of insulin signaling are clearly a part of the insulin resistant state, and may represent one of the earliest manifestations of insulin resistance. We will use BRET to explore the hypothesis that abnormal insulin signaling kinetics is the earliest detectable manifestation of insulin resistance, and to describe the mechanism behind this abnormality. PUBLIC STATEMENT : Insulin resistance, universal among persons with obesity and type II diabetes mellitus, is a major cause of health care expenditures in the U.S. Developing new techniques to study insulin resistance is a major goal of diabetes research. This proposal uses a novel technology, bioluminescence resonance energy transfer, to study insulin resistance in real time in live cultured cells.
描述(由申请人提供): 胰岛素抵抗存在于所有II型糖尿病患者中,了解胰岛素抵抗的原因将导致这种疾病的新治疗方法。为了更好地了解胰岛素抵抗发生的机制,需要在细胞培养模型中研究胰岛素抵抗的新技术。本文概述的研究将通过使用一种新的成像技术,生物发光共振能量转移(BRET)来实现这一目标。BRET使用荧光细胞内报告分子来测量活细胞中真实的酶活性和蛋白质-蛋白质相互作用,并且具有极大地推进我们对胰岛素信号传导的理解的潜力。 细胞代谢信号的一个重要但被低估的方面是受体串扰的作用。例如,在脂肪细胞中,在有利于能量储存(脂肪生成)的胰岛素信号传导和有利于能量释放(脂肪分解)的儿茶酚胺信号传导之间存在平衡。这些激素的受体之间的相互作用在维持正常的代谢稳态中起着关键作用。由于串扰,胰岛素信号传导的异常不仅影响胰岛素信号传导途径,而且影响儿茶酚胺信号传导途径。我们已经表明,这两个激素信号系统之间的一个重要的网站是在受体调节蛋白β-arrestin的水平。使用BRET,我们将测量胰岛素受体(和IGF-1受体)和β-抑制蛋白之间相互作用的几个方面。 BRET还为我们提供了一种前所未有的能力,可以在活细胞中真实的时间内测量胰岛素信号的动力学。胰岛素信号传导的异常动力学显然是胰岛素抵抗状态的一部分,并且可能代表胰岛素抵抗的最早表现之一。我们将使用BRET来探讨胰岛素信号动力学异常是胰岛素抵抗最早可检测到的表现这一假设,并描述这种异常背后的机制。 公开声明:胰岛素抵抗,普遍存在于肥胖和II型糖尿病患者中,是美国医疗保健支出的主要原因。开发研究胰岛素抵抗的新技术是糖尿病研究的主要目标。该方案采用生物发光共振能量转移技术,在活的培养细胞中真实的时间内研究胰岛素抵抗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER J HUPFELD其他文献

CHRISTOPHER J HUPFELD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER J HUPFELD', 18)}}的其他基金

Using BRET to measure insulin resistance and receptor cross-talk
使用 BRET 测量胰岛素抵抗和受体串扰
  • 批准号:
    7253280
  • 财政年份:
    2006
  • 资助金额:
    $ 7.73万
  • 项目类别:
Insulin, beta-Arrestin 1, and GPCR Signaling
胰岛素、β-抑制蛋白 1 和 GPCR 信号转导
  • 批准号:
    7239561
  • 财政年份:
    2003
  • 资助金额:
    $ 7.73万
  • 项目类别:
Insulin, beta-Arrestin 1, and GPCR Signaling
胰岛素、β-抑制蛋白 1 和 GPCR 信号转导
  • 批准号:
    7091392
  • 财政年份:
    2003
  • 资助金额:
    $ 7.73万
  • 项目类别:
Insulin, beta-Arrestin 1, and GPCR Signaling
胰岛素、β-抑制蛋白 1 和 GPCR 信号转导
  • 批准号:
    6895220
  • 财政年份:
    2003
  • 资助金额:
    $ 7.73万
  • 项目类别:
Insulin, beta-Arrestin 1, and GPCR Signaling
胰岛素、β-抑制蛋白 1 和 GPCR 信号转导
  • 批准号:
    6801453
  • 财政年份:
    2003
  • 资助金额:
    $ 7.73万
  • 项目类别:
Insulin, beta-Arrestin 1, and GPCR Signaling
胰岛素、β-抑制蛋白 1 和 GPCR 信号转导
  • 批准号:
    6678438
  • 财政年份:
    2003
  • 资助金额:
    $ 7.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了